Manus Rogan
Co-Founder & Managing Partner @ Fountain Healthcare Partners
Dublin, Ireland
Manus Rogan is a Series B investor at Fountain Healthcare Partners in Dublin focused on Biotechnology and Medical. Manus Rogan is based out of Dublin, Dublin and is the Co-Founder & Managing Partner of Fountain Healthcare Partners. Manus previously worked at GlaxoSmithkline as a product development. Manus Rogan attended the Trinity College Dublin.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries Manus Rogan invests in
Stages Manus Rogan invests in
Countries Manus Rogan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (41%)
- Medical 5 (29%)
- Health Care 5 (29%)
- Biopharma 2 (12%)
- Medical Device 2 (12%)
Stage
- Series B 4 (24%)
- Series A 3 (18%)
- Post-IPO Equity 3 (18%)
- Series C 1 (6%)
- Private Equity 1 (6%)
Country
- Ireland 6 (35%)
- United States 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $125M / Private Equity / Feb 26, 2024 | ||
| Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $16.6M / Series B / Apr 13, 2023 | ||
| Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $108M / Private Equity / Feb 16, 2021 | ||
| Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $12.4M / Series B / Oct 20, 2020 | ||
| Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic HematopoieticStem Cell Transplantation (HSCT) in these patients. | $35.4M / Series A / Oct 12, 2020 | ||
| Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $8.7M / Series A / Sep 26, 2019 | ||
| Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's,Alzheimer's, atherosclerosis, and type 2 diabetes.The company was incorporated in 2016 and is headquartered in Dublin, Ireland. | $45.8M / Series B / Nov 19, 2018 | ||
| Mainstay Medical is a global medical device company headquartered in Dublin, Ireland and with operations in the United States and Australia. They are partnering with scientists and clinical experts to deliver innovative therapies for the large underserved population of people with debilitating chronic low back pain. | $37.5M / Post-IPO Equity / Feb 15, 2018 | ||
| Inflazome is a biotech company that develops orally available drugs to address inflammatory diseases by targeting inflammasomes. The company's drugs block inflammasome signals, eliminating a root cause of inflammation, enabling healthcare institutions to avail targeted therapies for inflammatory diseases such as Parkinson's,Alzheimer's, atherosclerosis, and type 2 diabetes.The company was incorporated in 2016 and is headquartered in Dublin, Ireland. | $17M / Series A / Sep 11, 2016 | ||
| Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'. | $7.7M / Series A / Sep 29, 2015 | ||
| See all 17 investments → | |||
Co-Investors
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Fountain Healthcare Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aidan King
Co-Founder & Managing Partner
|
|||
Ena Prosser
Partner
|
|||
Justin Lynch
Partner & CFO
|
|||
|
Manus Rogan
Co-Founder & Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Manus Rogan invest in?
Manus Rogan invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Manus Rogan?
Public channels for Manus Rogan include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Manus Rogan last invest?
The most recent investment recorded for Manus Rogan closed in Feb 2024. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
